VEGFA and hereditary clear cell renal cell carcinoma: The first proof-of-concept of combining anti-VEGF-A and PD-1/PD-L1 inhibitors has been brought in a renal cell carcinoma model [68], in which a combination of bevacizumab (anti-VEGF) and atezolizumab (anti-PD-L1) increased intratumoral expression of MHC class I, Th1 markers and effector T cells, leading to an increased antitumor effect.